☆ 4.4 Editorial Material

NLA Task Force on Statin Safety-2014 update

JOURNAL OF CLINICAL LIPIDOLOGY (2014)

期刊

JOURNAL OF CLINICAL LIPIDOLOGY

卷 8, 期 3, 页码 S1-S4

出版社

ELSEVIER SCIENCE INC

DOI: 10.1016/j.jacl.2014.03.003

关键词

Statins; Statin drug; Statin muscle; Statin intolerance; Statin brain; Statin liver; Statin diabetes

类别

Pharmacology & Pharmacy

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Cardiac & Cardiovascular Systems

Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment

James P. Howard, Frances A. Wood, Judith A. Finegold, Alexandra N. Nowbar, David M. Thompson, Ahran D. Arnold, Christopher A. Rajkumar, Susan Connolly, Jaimini Cegla, Chris Stride, Peter Sever, Christine Norton, Simon A. M. Thom, Matthew J. Shun-Shin, Darrel P. Francis

Summary: The study found that the majority of symptoms caused by statin tablets were actually due to the placebo effect, suggesting that clinicians should be cautious when attributing symptoms to the medication. The research also indicated that there was no significant difference between abandoning statins and placebos, and the relief of symptoms after stopping medication was similar in both groups.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Management of patients with statin intolerance

Alexandra Nicole Martirossian, Anne Carol Goldberg

Summary: Atherosclerotic cardiovascular disease is a major cause of disability and death, and statins have become a crucial treatment and prevention for it. Despite the proven benefits of statins, many patients discontinue their usage, with muscle symptoms as a commonly stated reason. This article aims to review the literature on statin safety, particularly regarding muscle-related adverse effects, analyze adverse effects, and propose various treatment strategies for statin-intolerant patients.

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes

Stefano Ciardullo, Gianluca Perseghin

Summary: The study found that the use of statins in patients with type 2 diabetes could reduce the risk of advanced liver fibrosis, with no significant interaction with steatosis. Therefore, specific randomized controlled trials with statins are recommended due to the lack of approved therapies for NAFLD-fibrosis.

METABOLISM-CLINICAL AND EXPERIMENTAL (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Application of 3D Hepatic Plate-Like Liver Model for Statin-Induced Hepatotoxicity Evaluation

Jiecheng Xu, Daogang Pan, Wei Liao, Zhidong Jia, Mingxin Pan, Jun Weng, Xu Han, Shao Li, Yang Li, Kangyan Liang, Shuqin Zhou, Qing Peng, Yi Gao

Summary: The 3D-P co-culture system demonstrated enhanced liver-specific functions and bile excretion, making it a promising tool for assessing acute/chronic drug hepatotoxicity.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Statin-associated muscle symptoms-A review: Individualizing the approach to optimize care

Barbara S. Wiggins, James M. Backes, Daniel Hilleman

Summary: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, known as statins, are considered the first-line pharmacologic therapy for reducing LDL-C. However, they can have possible adverse effects, with musculoskeletal problems being the most common side effect. Nonadherence to statin therapy can have a negative impact on patient care, thus understanding risk factors, diagnosis, and management is important for optimizing care.

PHARMACOTHERAPY (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis

Daniele Pastori, Arianna Pani, Arianna Di Rocco, Danilo Menichelli, Gianluca Gazzaniga, Alessio Farcomeni, Laura D'Erasmo, Francesco Angelico, Maria Del Ben, Francesco Baratta

Summary: The study found that statin treatment significantly reduced ALT, AST, and GGT levels in NAFLD patients in interventional studies, while observational studies showed no significant effect, indicating the liver safety of statins in NAFLD patients.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)

添加到收藏夹

Review Peripheral Vascular Disease

A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms

Carl E. Orringer, Jelani K. Grant, Lale Tokgozoglu

Summary: The purpose of this review is to provide a systematic approach to managing patients with statin-attributed muscle symptoms. Recent findings include the prevalence of statin intolerance, the role of the nocebo effect, key findings in patients' history and laboratory studies, the potential value of coronary calcium scoring, and the importance of shared decision-making in considering statin re-initiation. Most patients with statin-attributed muscle symptoms can achieve successful ASCVD risk reduction through treatment with statins or a combination of statins and non-statins.

CURRENT ATHEROSCLEROSIS REPORTS (2022)

添加到收藏夹

Review Pharmacology & Pharmacy

Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit

Carl E. Orringer, Michael J. Blaha, Neil J. Stone

Summary: Statin therapy can reduce the incidence of cardiovascular events in adults with intermediate or high cardiovascular risk; muscle complaints are the most common reported symptoms; informed clinician-patient discussion and shared decision making are necessary for achieving the best outcomes.

JOURNAL OF CLINICAL LIPIDOLOGY (2021)

添加到收藏夹

Article Geriatrics & Gerontology

Statin use and discontinuation in Danes age 70 and older: a nationwide drug utilisation study

Wade Thompson, Dorte Ejg Jarbol, Jesper Bo Nielsen, Peter Haastrup, Anton Pottegard

Summary: The study found that approximately one in three Danes aged 70 and older were taking statins in 2016. The prevalence of statin use was generally stable in the 70 to 79 age group, but increased in the 80 and older age group. Around 19% of long-term statin users discontinued therapy between 2014 and 2016, with increasing age being the strongest predictor of statin discontinuation.

AGE AND AGEING (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Optimal statin use for prevention of sepsis in type 2 diabetes mellitus

Mingyang Sun, Yuan Tao, Wan-Ming Chen, Szu-Yuan Wu, Jiaqiang Zhang

Summary: This study aimed to investigate the dose-dependent protective effects of statins, specific classes of statins, and different intensities of statin use on sepsis risk in patients with type 2 diabetes mellitus (T2DM). The results showed that statin use can reduce the incidence of sepsis and septic shock in T2DM patients. Specific classes of statins and higher doses of statins were associated with a reduced risk of sepsis.

DIABETOLOGY & METABOLIC SYNDROME (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Statin therapy and sex hormones

Cosimo Andrea Stamerra, Paolo Di Giosia, Claudio Ferri, Paolo Giorgini, Zeljko Reiner, Thomas P. Johnston, Amirhossein Sahebkar

Summary: Statins may slightly impair adrenal and/or gonadal steroid hormone production, but do not cause clinically-relevant harmful effects on erectile function and spermatogenesis in men. They have beneficial effects in the treatment of polycystic ovary syndrome in women. Additional research is needed to provide specific clinical recommendations on this topic.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study

M. Casula, M. Gazzotti, F. Bonaiti, E. OImastroni, M. Arca, M. Averna, A. Zambon, A. L. Catapano

Summary: The PROSISA study found that 9.6% of dyslipidaemic patients reported statin-associated muscle symptoms (SAMS), with only one third of patients still reporting SAMS after dechallenge/rechallenge.

JOURNAL OF INTERNAL MEDICINE (2021)

添加到收藏夹

Article Cell Biology

Assessment of the Preventive Effect of L-carnitine on Post-statin Muscle Damage in a Zebrafish Model

Joanna Niedbalska-Tarnowska, Katarzyna Ochenkowska, Marta Migocka-Patrzalek, Magda Dubinska-Magiera

Summary: This study investigated the alleviating effect of L-carnitine on muscle damage in zebrafish larvae treated with lovastatin. The results showed that lovastatin exposure caused muscle disruption, and L-carnitine partially mitigated this muscle damage.

CELLS (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

LDL Reduction and Risk of Diabetes in Veteran Statin Users

Michaela Gross, Skai W. Schwartz, Yuri V. Sebastiao, Amy Alman, Jason L. Salemi, Pragati Ghimire-Aryal, Philip Foulis

Summary: This study found a significant association between LDL reduction following statin use and new-onset diabetes mellitus in veterans. The association may be explained by potential lifestyle modifications individuals may make when prescribed a statin, independent of the statin usage.

ANNALS OF PHARMACOTHERAPY (2023)

添加到收藏夹

Article Oncology

Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery

Elias Khajeh, Arash Dooghaie Moghadam, Pegah Eslami, Sadeq Ali-Hasan-Al-Saegh, Ali Ramouz, Saeed Shafiei, Omid Ghamarnejad, Sepehr Abbasi Dezfouli, Christian Rupp, Christoph Springfeld, Carlos Carvalho, Pascal Probst, Seyed Mostafa Mousavizadeh, Arianeb Mehrabi

Summary: This meta-analysis investigated the preventive effect of statins on HCC recurrence after liver surgery. The study found that patients who received statins had a lower rate of recurrence after liver surgery, and statins decreased the recurrence rate at 1 year, 3 years, and 5 years after surgery.

BMC CANCER (2022)

添加到收藏夹

Article Hematology

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

Connie B. Newman, David Preiss, Jonathan A. Tobert, Terry A. Jacobson, Robert L. Page, Larry B. Goldstein, Clifford Chin, Lisa R. Tannock, Michael Miller, Geetha Raghuveer, P. Barton Duell, Eliot A. Brinton, Amy Pollak, Lynne T. Braun, Francine K. Welty

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Deepak L. Bhatt, P. Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Ralph T. Doyle, Rebecca A. Juliano, Lixia Jiao, Craig Granowitz, Jean-Claude Tardif, Christie M. Ballantyne

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association

Don P. Wilson, Terry A. Jacobson, Peter H. Jones, Marlys L. Koschinsky, Catherine J. McNeal, Burge G. Nordestgaard, Cart E. Orringer

JOURNAL OF CLINICAL LIPIDOLOGY (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy

Terry A. Jacobson, Mary Katherine Cheeley, Peter H. Jones, Ralph La Forge, Kevin C. Maki, J. Antonio G. Lopez, Pin Xiang, Donald M. Bushnell, Mona L. Martin, Jerome D. Cohen

JOURNAL OF CLINICAL LIPIDOLOGY (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials

Keith C. Ferdinand, Terry A. Jacobson, Andrew Koren, Joseph Elassal, Desmond Thompson, Prakash Deedwania

JOURNAL OF CLINICAL LIPIDOLOGY (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association

Ann C. Skulas-Ray, Peter W. F. Wilson, William S. Harris, Eliot A. Brinton, Penny M. Kris-Etherton, Chesney K. Richter, Terry A. Jacobson, Mary B. Engler, Michael Miller, Jennifer G. Robinson, Conrad B. Blum, Delfin Rodriguez-Leyva, Sarah D. de Ferranti, Francine K. Welty

CIRCULATION (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk

Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki

JOURNAL OF CLINICAL LIPIDOLOGY (2019)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results

Brian Olshansky, Deepak L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Ralph T. Doyle, Rebecca A. Juliano, Lixia Jiao, Craig Granowitz, Jean-Claude Tardif, Cyrus Mehta, Rajat Mukherjee, Christie M. Ballantyne, Mina K. Chung

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI

Benjamin E. Peterson, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, C. Michael Gibson, Duane Pinto, Robert P. Giugliano, Matthew J. Budoff, Jean-Claude Tardif, Subodh Verma, Christie M. Ballantyne

Summary: Icosapent Ethyl significantly reduces the risk of recurrent cardiovascular events in patients with elevated triglycerides and a history of prior percutaneous coronary intervention.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of Icosapent Ethyl on Cardiovascular Risk Recuction in Patients With Heart Failure in REDUCE-IT

Senthil Selvaraj, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Rebecca A. Juliano, Lixia Jiao, Jean-Claude Tardif, Christie M. Ballantyne

Summary: This study aimed to investigate the treatment effects of icosapent ethyl in patients with heart failure (HF). The results showed that icosapent ethyl reduced triglyceride and hs-CRP levels in patients with HF, and had similar cardiovascular risk reduction effects.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking

Michael Miller, Deepak L. Bhatt, Ph Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Lixia Jiao, Jean-Claude Tardif, Christie M. Ballantyne, Matthew Budoff, R. Preston Mason

Summary: The study found that the use of IPE can reduce the risk of cardiovascular disease in smokers to the level observed in non-smokers.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT

Brian Olshansky, Deepak L. L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. A. Brinton, Terry A. A. Jacobson, Steven B. B. Ketchum, Ralph T. T. Doyle Jr, Rebecca A. A. Juliano, Lixia Jiao, Peter R. R. Kowey, James A. A. Reiffel, Jean-Claude Tardif, Christie M. M. Ballantyne, Mina K. K. Chung

Summary: In the REDUCE-IT study, icosapent ethyl (IPE) reduced cardiovascular events but was associated with increased atrial fibrillation/atrial flutter (AF) hospitalization. The study analyzed the relationships between IPE and outcomes in patients with or without prior AF and with or without in-study AF hospitalization. Overall, in-study AF hospitalization rates were higher in patients with prior AF, especially in those randomized to IPE. Serious bleeding rates also trended higher in these patients. However, patients with prior AF or in-study AF hospitalization showed consistent risk reductions in cardiovascular events with IPE.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group

Peter W. F. Wilson, Terry A. Jacobson, Seth S. Martin, Elizabeth J. Jackson, N-Anh Le, Michael H. Davidson, Hubert W. Vesper, Ruth Frikke-Schmidt, Christie M. Ballantyne, Alan T. Remaley

Summary: The measurement of lipoproteins is crucial for managing patients with coronary heart disease and atherosclerotic cardiovascular disease. Guidelines for lipid measurements have evolved to optimize cardiovascular risk assessment and prevention. Screening with nonfasting lipids is acceptable, and the use of non-HDL-C and alternative methods for estimating LDL-C are recommended, especially for patients with specific lipid profiles. Harmonization of advanced lipid measurement methods and timely follow-up after changes in lipid treatment are also emphasized for better clinical outcomes.

JOURNAL OF CLINICAL LIPIDOLOGY (2021)

添加到收藏夹

Meeting Abstract Cardiac & Cardiovascular Systems

Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT

William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Sarahfaye F. Dolman, Cheng Zhang, William E. Boden, Adam P. Bress, Jordan B. King, Philippe G. Steg, Eliot A. Brinton, Terry A. Jacobson, Jean Claude Tardif, Christie M. Ballantyne, Paul Kolm

CIRCULATION (2019)

添加到收藏夹

Correction Hematology

Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association (vol 39, pg e38, 2019)

Connie B. Newman, David Preiss, Jonathan A. Tobert, Terry A. Jacobson, Robert L. Page, Larry B. Goldstein, Clifford Chin, Lisa R. Tannock, Michael Miller, Geetha Raghuveer, P. Barton Duell, Eliot A. Brinton, Amy Pollak, Lynne T. Braun, Francine K. Welty

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.